For instance, interventions designed to inhibit the signaling pathways of CCL2 and CXCL10 may help to reduce excessive immune cell recruitment and activation, thereby limiting inflammation and preventing the escalation of lung injury in COVID-19 patients. The gene discussed is CCL2; the disease is COVID-19.